Get the Stockscreener App
77.58
4.89%
-3.99
Dianthus Therapeutics Inc stock is traded at $77.58, with a volume of 1.32M.
It is down -4.89% in the last 24 hours and down -26.95% over the past month.
Dianthus Therapeutics Inc. is a clinical-stage biotechnology company dedicated to developing potentially best-in-class therapies for patients with severe autoimmune diseases. The company operates as a single segment and has one reportable segment, focusing on creating next-generation treatments to revolutionize the management of severe autoimmune conditions. The team comprises experienced biotech and pharma executives. The pipeline includes the potential of Claseprubart, a next-generation complement therapeutic.
See More
Previous Close:
$81.57
Open:
$81.42
24h Volume:
1.32M
Relative Volume:
1.47
Market Cap:
$4.34B
Revenue:
$1.34M
Net Income/Loss:
$-173.66M
P/E Ratio:
-18.75
EPS:
-4.1385
Net Cash Flow:
$-130.49M
1W Performance:
-9.16%
1M Performance:
-26.95%
6M Performance:
-13.80%
1Y Performance:
+125.39%
1-Day Range:
$77.25
$81.46
1-Week Range:
$77.25
$86.61
52-Week Range:
$32.22
$117.88
Dianthus Therapeutics Inc Stock (DNTH) Company Profile
Name
Dianthus Therapeutics Inc
Sector
Industry
Phone
929-999-4055
Address
7 TIMES SQUARE, NEW YORK
Compare DNTH vs VRTX, MRNA, REGN, ARGX, RVMD
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
DNTH
Dianthus Therapeutics Inc
|
77.58 | 4.34B | 1.34M | -173.66M | -130.49M | -4.1385 |
VRTX
Vertex Pharmaceuticals Inc
|
485.22 | 122.98B | 12.34B | 4.34B | 3.71B | 16.87 |
MRNA
Moderna Inc
|
216.25 | 86.33B | 2.23B | -3.19B | -1.60B | -8.1462 |
REGN
Regeneron Pharmaceuticals Inc
|
753.12 | 77.54B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
802.64 | 50.47B | 4.16B | 1.29B | 734.26M | 19.58 |
RVMD
Revolution Medicines Inc
|
188.44 | 40.39B | 742.00K | -1.37B | -1.07B | -7.0731 |
Dianthus Therapeutics Inc Stock (DNTH) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Sep-11-26 | Initiated | JP Morgan | Overweight |
| Sep-04-26 | Initiated | Citigroup | Buy |
| Apr-09-26 | Initiated | Wolfe Research | Outperform |
| Mar-10-26 | Upgrade | Raymond James | Outperform → Strong Buy |
| Oct-14-25 | Initiated | Truist | Buy |
| Jul-02-25 | Initiated | William Blair | Outperform |
| Dec-20-24 | Initiated | TD Cowen | Buy |
| Oct-03-24 | Initiated | Oppenheimer | Outperform |
| Jul-26-24 | Initiated | Robert W. Baird | Outperform |
| Jun-27-24 | Initiated | Cantor Fitzgerald | Overweight |
| May-16-24 | Initiated | H.C. Wainwright | Buy |
| Feb-15-24 | Initiated | Stifel | Buy |
| Dec-26-23 | Initiated | Jefferies | Buy |
| Nov-22-23 | Initiated | Wedbush | Outperform |
| Oct-30-23 | Initiated | Guggenheim | Buy |
| Sep-28-23 | Initiated | Raymond James | Outperform |
| Aug-25-22 | Downgrade | Goldman | Buy → Neutral |
| Jan-06-22 | Upgrade | Goldman | Neutral → Buy |
| Aug-20-21 | Resumed | Goldman | Neutral |
| Aug-03-21 | Downgrade | JP Morgan | Overweight → Neutral |
| Jul-22-21 | Reiterated | B. Riley Securities | Buy |
| Jun-29-21 | Initiated | Cantor Fitzgerald | Overweight |
| Jun-15-21 | Initiated | BTIG Research | Buy |
| May-18-21 | Initiated | B. Riley Securities | Buy |
| Jan-07-21 | Initiated | Mizuho | Buy |
| Jun-08-20 | Upgrade | Goldman | Neutral → Buy |
| Mar-25-19 | Downgrade | Goldman | Buy → Neutral |
| Mar-15-19 | Initiated | Raymond James | Outperform |
View All
Dianthus Therapeutics Inc Stock (DNTH) Latest News
Spyre Therapeutics, Inc. (SYRE) stock price, news, quote and history - Yahoo Finance Australia
Spyre Therapeutics, Inc. (SYRE) Stock Price, News, Quote & History - Yahoo! Finance Canada
Dianthus Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - manilatimes.net
Dianthus Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - GlobeNewswire Inc.
Dianthus Therapeutics, Inc. (DNTH) Stock Price, News, Quote & History - ca.finance.yahoo.com
Dianthus (NASDAQ: DNTH) officer set to sell 20,000 shares - Stock Titan
Dianthus Therapeutics at Cantor conference: pipeline gains speed By Investing.com - Investing.com South Africa
Dianthus Therapeutics at Cantor conference: pipeline gains speed By Investing.com - Investing.com Canada
DNTH: Claseprubart's strong clinical results and pipeline advances are driving rapid growth and expansion - TradingView
Dianthus Therapeutics at Cantor conference: pipeline gains speed By Investing.com - Investing.com UK
Dianthus: Hold, Based On Competitor C1s' CIDP Setback And Continued Claseprubart Advancement - Seeking Alpha
Dianthus (DNTH) Piles Up Clinical Wins While Its Losses Widen - Yahoo Finance
Dianthus Therapeutics R&D Head Randhawa Simrat Retains 4,000 Shares After Exercising and Selling Options - kalkinemedia.com
Dianthus gains new Buy from Citi on multi-blockbuster potential for lead drug - Seeking Alpha
Dianthus Therapeutics EVP Simrat Randhawa Executes Stock Options and Sells Shares Under Rule 10b5-1 Plan - Kalkine Media
Dianthus Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - manilatimes.net
Dianthus Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - marketscreener.com
Officer at Dianthus (NASDAQ: DNTH) lines up 2026 stock sale after option exercise - Stock Titan
Dianthus Therapeutics to Participate in Three Investor Conferences During September - manilatimes.net
ZLAB Stock Price, Quote & News - Syfe
Dianthus Therapeutics: The C1s Shakeout Strengthens The Bull Case - Seeking Alpha
Dianthus (DNTH) Quarterly Figures: Profit Per Share Falls Below Its Benchmark for the Current Session - vinanet.vn
Bank of America Corp DE Trims Stake in Dianthus Therapeutics, Inc. $DNTH - MarketBeat
Royal Bank of Canada Has $1.60 Million Stock Holdings in Dianthus Therapeutics, Inc. $DNTH - MarketBeat
Eagle Health Investments LP Takes Position in Dianthus Therapeutics, Inc. $DNTH - MarketBeat
Dianthus Therapeutics (NASDAQ:DNTH) Sets New 52-Week HighStill a Buy? - MarketBeat
Simon Read Sells 2,778 Shares of Dianthus Therapeutics (NASDAQ:DNTH) Stock - MarketBeat
Dianthus Therapeutics director Simon Read sells $326,553 in stock By Investing.com - Investing.com Australia
Dianthus Therapeutics director Simon Read sells $326,553 in stock By Investing.com - Investing.com Nigeria
Dianthus Therapeutics director Simon Read sells $326,553 in stock By Investing.com - Investing.com South Africa
Dianthus Therapeutics director Simon Read sells $326,553 in stock - Investing.com
Dianthus Therapeutics director Simon Read sells $326,553 in stock By Investing.com - Investing.com India
Dianthus Therapeutics director Simon Read sells $326,553 in stock - Investing.com
Dianthus (DNTH) Stock: Ends Down by 2.20% at $113.00 at the Close; Market Levels: the Supplied Trading Band Runs From $107.35 to $118.65 at the ClosePre-Earnings Momentum - vinanet.vn
Handelsbanken Fonder AB Invests $1.49 Million in Dianthus Therapeutics, Inc. $DNTH - MarketBeat
Dianthus Therapeutics Director Simon Read Executes Stock Option Exercise and Sells Shares Under 10b5-1 Plan - kalkinemedia.com
Dianthus Therapeutics, Inc. (NASDAQ:DNTH) Receives Average Rating of "Moderate Buy" from Analysts - MarketBeat
TimesSquare Capital Management LLC Acquires Shares of 166,357 Dianthus Therapeutics, Inc. $DNTH - MarketBeat
SCS Capital Management LLC Takes Position in Dianthus Therapeutics, Inc. $DNTH - MarketBeat
Stifel Maintains Dianthus Therapeutics(DNTH.US) With Buy Rating, Maintains Target Price $133 - Moomoo
Walleye Capital LLC Takes Position in Dianthus Therapeutics, Inc. $DNTH - MarketBeat
Dianthus Therapeutics SVP Adam M. Veness Exercises 15,000 Stock Options at $18.17 Each - Kalkine Media
Dianthus Therapeutics (NASDAQ:DNTH) Reaches New 52-Week HighTime to Buy? - MarketBeat
Dianthus Therapeutics stock hits 52-week high at 114.64 USD By Investing.com - Investing.com Nigeria
Dianthus Therapeutics stock hits 52-week high at 114.64 USD By Investing.com - Investing.com Canada
Dianthus Therapeutics stock hits 52-week high at 114.64 USD - Investing.com
Dianthus Therapeutics stock hits 52-week high at 114.64 USD By Investing.com - Investing.com UK
Sirenia Capital reveals 1.70M-share DNTH stake in Dianthus Therapeutics (DNTH) - Stock Titan
Dianthus Therapeutics (DNTH): Wellington group discloses 3.23M-share, 5.9% passive stake - Stock Titan
Dianthus therapeutics director Simon Read sells $304k in stock By Investing.com - Investing.com South Africa
Dianthus Therapeutics Inc Stock (DNTH) Financials Data
Revenue
Net Income
Cash Flow
EPS
Dianthus Therapeutics Inc Stock (DNTH) Insider Trading
| Insider Trading | Relationship | Date | Transaction | Cost | #Shares | Value ($) | #Shares Total |
|---|---|---|---|---|---|---|---|
| EDWARD CARR | Officer |
Sep 17 '26 |
Proposed Sale |
102.49 |
20,000 |
2,049,800 |
0 |
| CARR EDWARD | CHIEF ACCOUNTING OFFICER |
Sep 17 '26 |
Sale |
101.38 |
20,000 |
2,027,646 |
0 |
| Randhawa Simrat | EVP, Head of R&D |
Sep 01 '26 |
Sale |
106.41 |
23,124 |
2,460,690 |
4,000 |
| Randhawa Simrat | EVP, Head of R&D |
Sep 01 '26 |
Option Exercise |
20.63 |
23,124 |
477,047 |
27,124 |
| SIMRAT RANDHAWA | Officer |
Sep 01 '26 |
Proposed Sale |
105.61 |
23,124 |
2,442,126 |
0 |
| Read Simon | Director |
Aug 19 '26 |
Sale |
117.55 |
2,778 |
326,554 |
0 |
| Read Simon | Director |
Aug 19 '26 |
Option Exercise |
18.36 |
2,778 |
51,004 |
2,778 |
| Veness Adam M | SVP, General Counsel and Sec. |
Aug 13 '26 |
Option Exercise |
18.17 |
15,000 |
272,550 |
15,000 |
| Read Simon | Officer |
Aug 10 '26 |
Proposed Sale |
112.50 |
5,550 |
624,375 |
0 |
| ADAM VENESS | Officer |
Aug 10 '26 |
Proposed Sale |
108.92 |
16,167 |
1,760,910 |
0 |
0.20%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):